Catalyst
Slingshot members are tracking this event:
Alnylam Initiated Dosing in PNH Patients in Phase 1/2 Clinical Trial for ALN-CC5; expects to report initial PNH patient data from this ongoing clinical study in mid-2016
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| ALNY |
|
|
||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Jun 11, 2016
Occurred Source:
http://investors.alnylam.com/releasedetail.cfm?ReleaseID=975341
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Paroxysmal Nocturnal Hemoglobinuria, Pnh, Aln-cc5
